Cart
sales@molnova.com
Latikafusp
CAS No. 2552814-07-8
Latikafusp( —— )
Catalog No. M36804 CAS No. 2552814-07-8
Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 818 | Get Quote |
|
| 5MG | 1311 | Get Quote |
|
| 10MG | 1596 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLatikafusp
-
NoteResearch use only, not for human use.
-
Brief DescriptionLatikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.
-
DescriptionLatikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2552814-07-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Greg Durm, et al. Abstract CT205: Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, PD-1 antibody x IL-21 mutein bifunctional fusion protein, in patients with advanced solid tumors. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301. ?
molnova catalog
related products
-
Tislelizumab
Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.
-
PDL-1 cpd 10
PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
-
BMS-1166
BMS-1166 is a?potent PD-1/PD-L1 interaction inhibitor with IC50 of 1.4 nM in a homogenous time-resolved fluorescence binding assay.
